← Atlas Theme · spans 1 topics

The Phase 3 trial is losing its monopoly on FDA proof.

FDA accepted the first Keytruda biosimilar on analytical comparability plus a PK study alone, while ARPA-H's SURPASS builds digital-twin, phaseless trial engines — computational and analytical substitutes are displacing the comparative efficacy trial as the basis of regulatory confidence.

Topics it spans

Findings citing it

—

Evidence window

The convergence

The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:

Science & Health

FDA Expands Anktiva to Papillary-Only BCG-Unresponsive Bladder Cancer — First Approval Covering That Population, by Extrapolation from the CIS Cohort

Approving a brand-new patient population with zero new trials shows cross-cohort extrapolation displacing the comparative efficacy study.

Science & Health

First Keytruda Biosimilar Under FDA Review: Formycon/Zydus' FYB206 Accepted Without a Comparative Phase 3 Trial — Decision Expected Q3 2027

The world's best-selling biologic can now be copied on analytical comparability plus a PK study alone, ending the Phase 3 monopoly at the top of oncology.

Science & Health

HHS and FDA's "Operation Trialblazer": Accelerating Clinical Trials — Now with ARPA-H's SURPASS, STACK, COMMONS, and CINCH

Digital-twin, phaseless trial engines aim to build regulatory confidence without conventional comparative trials, extending the displacement of the Phase 3 monopoly into trial design itself.